Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
4d Pharma Plc LSE:DDDD London Ordinary Share GB00BJL5BR07 ORD 0.25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  1.50 1.27% 119.50 119.00 120.00 120.00 114.50 120.00 714,195 13:30:45
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -29.4 -36.8 - 157

4d Pharma Share Discussion Threads

Showing 13076 to 13099 of 17400 messages
Chat Pages: Latest  528  527  526  525  524  523  522  521  520  519  518  517  Older
DateSubjectAuthorDiscuss
28/10/2020
08:16
Lol..lol..
rastamouse
28/10/2020
08:13
Once David finished selling this will be back up.
avsome1968
28/10/2020
07:25
Astra Zeneca out with a RNS today boasting FDA have given them a Priority Review "The Food and Drug Administration (FDA) grants Priority Review to applications for medicines that offer significant advances over available options by demonstrating safety or efficacy improvements, preventing serious conditions, or enhancing patient compliance. The Prescription Drug User Fee Act date, the FDA action date for their regulatory decision, will be during the first quarter of 2021." Suspect 4D and Merck will be working on this in readiness for Phase II data on MRx0518 (although given serious unmet need maybe the Phase I SAFETY and EFFICACY will be enough to get them to jump the queue?)
the stigologist
28/10/2020
07:20
Even at this late stage in the whole covid story Big Pharma investing in early stage development of potential solutions from small bios e.g. Novartis with a $200m+ headline deal ($50m upfront) with Molecular Partners today for drug candidates not even in Phase I yet ! htTps://investegate.co.uk/novartis-ag-chf0-50-regd-/gnw/novartis-announces-collaboration-with-molecular-partners-to-develop-two-darpin--174--therapies-designed-for-potential-use-against-covid-19/20201028061500H4732/ "Multiple treatment options increases the likelihood of reaching and treating patients around the world and, in addition, may be especially important for certain populations at greater risk who may benefit from a prophylactic treatment."
the stigologist
27/10/2020
23:51
I see a pretty busy news/update pipeline, all the way to mid/late January. And from there, who knows how things might have developed. All I do know is that with an enlarged OPEN trial running in a space that has already shown very promising results, you want exposure.....because the news can reveal itself at any time. And for that reason, as I've said, I'll remain in all the way through till late spring and, if the opportunity allows, add stock when I think it looks silly cheap. An update on our >1B$ vaccines collaboration would be appreciated. Confidentiality clauses abound and since this deal was signed prior to Covid, it would certainly be interesting to learn if they have indeed since switched into this indication. (The deal was for up to three indications). MERCK have kept a rather low profile with regards to the Covid vaccine space, which indeed was recently deemed newsworthy in itself. An update in that direction would certainly put the cat amongst the pigeons, but even if they're busy on other indications, an update on this deal can only add value to what limited information is already in the public domain. I think the BOD recognise the argument for disclosing more about this collaboration and feel it will come at some point. Good luck and ADYOR. All eyes on the conference.
realist1950
27/10/2020
23:38
Bermudashorts27 Oct '20 - 21:15 - 12857 of 12868 ...................... A good spot there, Bermudashorts27. Marked up.
realist1950
27/10/2020
23:28
Hope so Stig.200 pounds here we come!!!!Peace out
rastamouse
27/10/2020
23:26
And the big "what if" moment could be a combination or all 4 shots coming good one after the other ! That would be a game changer !
thepaddedcell
27/10/2020
23:18
No idea what could be our 'breakout' moment as we don't have a Phase III trial 'success' due However worth noting Seres's 'success' is a 'success' in inverted commas because their trial was 'underpowered' with only c.200 participants and the FDA have refused Seres' request for a meeting to expedite approval. Seres are having to thus recruit more patients and will have to wait for the extended study to complete before they reach commercialisation Meanwhile we have a chance of reaching commercialisation milestone prior to them possibly in TWO indications 1. Cancer - owing to safety profile, combination with Industry leader Keytruda/Merck, MD Anderson links to FDA etc there is high chance MRx0518 could be approved in 2021 and rapidly commercialised alongside $20bn p.a. Keytruda 2. Covid - again owing to MRx0004 safety profile, given emergency nature of pandemic, IF MRx0004 demonstrates any efficacy it has the chance to be fast-tracked into commercialisation Other potential BREAKOUT catalysts could be :- Any Merck Vaccine - milestone payment or even a positive official progress report Listing on NASDAQ in January 2021 under ticker LBPS I make it about 4 shots on goal in the next few months which could give us our Seres type breakout moment
the stigologist
27/10/2020
23:17
Slow and steady wins the race ! Still up around 20% on this time last week.
thepaddedcell
27/10/2020
23:15
From the "UPS" thread ..... AAAA 116p Today's early drop reached 61.8% Fibonacci retracement the normal point of bounce back, and also the 110p merger terms. Time to bounce back to higher points help by the Covid 19 getting worse.
master rsi
27/10/2020
21:53
In Halloween week a bit spooky how our weekly chart is setting up exactly like Seres MCRB prior to their breakout on Phase III data... The share price towards the bottom of the weekly Moving Average...
the stigologist
27/10/2020
21:50
Bermudashorts - legend. It feels like a scene from the shining at the moment, scary but you know what is coming.
devonlad
27/10/2020
21:36
We're just days/weeks/months away from deals of this type and/or actual commercial launch and sales into the $200 Billion a year Cancer Therapy market
the stigologist
27/10/2020
21:31
The 4th Annual Next-Gen Immuno-Oncology Congress demonstrates how young this huge market is and the exciting development/combination options. Great to see 4D will be there hob-nobbing with the Leaders in the space (No other microbiome player attending AFAICS) hTtps://events.marketsandmarkets.com/4th-annual-marketsandmarkets-next-gen-immuno-oncology-congress/speakers 30+ experts from academia and industry will be presenting their current work in Immuno-Oncology, Latest updates on regulatory guidelines and approvals, Validation markers for tumor-derived T-cell subpopulations, NextGen T-Cell and CAR-T Cell therapy, Personalized Medicine, Biomarkers and Cancer Immunotherapy
the stigologist
27/10/2020
21:24
Yes - VERY good find.
someuwin
27/10/2020
21:18
Great find Bermudashorts!
ambyth
27/10/2020
21:15
Devonlad Both Alex Stevenson and Imke Mulder are involved in the January event. Alex Stevenson is on the panel for the European Microbiome Leaders Discussion and Dr Mulder is presenting later in the day - details of her presentation below, last line is interesting:- MicroRx Single Strain Live-Biotherapeutics: POC Clinical Data and Future Considerations - From preclinical models to proof of concept in patients - Next phase of clinical development - Second generation MicroRx LBPs and new target diseases Https://microbiome-europe.com/whats-on/day-one/
bermudashorts
27/10/2020
21:03
January event could be quite interesting.
devonlad
27/10/2020
20:42
Packed schedule in the weeks/months ahead
the stigologist
27/10/2020
20:26
so a woke version of Fingerbobs then
lionheart72
27/10/2020
20:21
The vermin needs to be removed
blueblood
27/10/2020
20:13
Rastamouse is a British animated stop motion children's TV series created by Genevieve Webster and Michael De Souza and produced by Three Stones Media/The Rastamouse Company for CBeebies. The show follows crime busting mouse reggae band Da Easy Crew, who split their time between making music and solving mysteries for Da President of Mouseland..........say no more!
showmethemoneyhoney01
27/10/2020
19:54
50 Day MA at around 1.22Hopefully it should test that and climb above soon.If it does then 1.80 is on again.If not the 1.00 could be tested.
rastamouse
Chat Pages: Latest  528  527  526  525  524  523  522  521  520  519  518  517  Older
ADVFN Advertorial
Your Recent History
LSE
DDDD
4d Pharma
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210120 13:57:11